During early fasting, increases in skeletal muscle proteolysis liberate free amino acids for hepatic gluconeogenesis in response to pancreatic glucagon. Hepatic glucose output diminishes during the late protein-sparing phase of fasting, when ketone body production by the liver supplies compensatory fuel for glucose-dependent tissues 1-4 . Glucagon stimulates the gluconeogenic program by triggering the dephosphorylation and nuclear translocation of the CREB regulated transcription coactivator 2 (CRTC2; also known as TORC2), while parallel decreases in insulin signalling augment gluconeogenic gene expression through the dephosphorylation and nuclear shuttling of forkhead box O1 (FOXO1) 5-7 . Here we show that a fasting-inducible switch, consisting of the histone acetyltransferase p300 and the nutrient-sensing deacetylase sirtuin 1 (SIRT1), maintains energy balance in mice through the sequential induction of CRTC2 and FOXO1. After glucagon induction, CRTC2 stimulated gluconeogenic gene expression by an association with p300, which we show here is also activated by dephosphorylation at Ser 89 during fasting. In turn, p300 increased hepatic CRTC2 activity by acetylating it at Lys 628, a site that also targets CRTC2 for degradation after its ubiquitination by the E3 ligase constitutive photomorphogenic protein (COP1) 8 . Glucagon effects were attenuated during late fasting, when CRTC2 was downregulated owing to SIRT1-mediated deacetylation and when FOXO1 supported expression of the gluconeogenic program. Disrupting SIRT1 activity, by liver-specific knockout of the Sirt1 gene or by administration of a SIRT1 antagonist, increased CRTC2 activity and glucose output, whereas exposure to SIRT1 agonists reduced them. In view of the reciprocal activation of FOXO1 and its coactivator peroxisome proliferator-activated receptor-c coactivator-1a (PGC-1a, encoded by Ppargc1a) by SIRT1 activators 9-12 , our results illustrate how the exchange of two gluconeogenic regulators during fasting maintains energy balance.
During early fasting, increases in skeletal muscle proteolysis liberate free amino acids for hepatic gluconeogenesis in response to pancreatic glucagon. Hepatic glucose output diminishes during the late protein-sparing phase of fasting, when ketone body production by the liver supplies compensatory fuel for glucose-dependent tissues [1] [2] [3] [4] . Glucagon stimulates the gluconeogenic program by triggering the dephosphorylation and nuclear translocation of the CREB regulated transcription coactivator 2 (CRTC2; also known as TORC2), while parallel decreases in insulin signalling augment gluconeogenic gene expression through the dephosphorylation and nuclear shuttling of forkhead box O1 (FOXO1) [5] [6] [7] . Here we show that a fasting-inducible switch, consisting of the histone acetyltransferase p300 and the nutrient-sensing deacetylase sirtuin 1 (SIRT1), maintains energy balance in mice through the sequential induction of CRTC2 and FOXO1. After glucagon induction, CRTC2 stimulated gluconeogenic gene expression by an association with p300, which we show here is also activated by dephosphorylation at Ser 89 during fasting. In turn, p300 increased hepatic CRTC2 activity by acetylating it at Lys 628, a site that also targets CRTC2 for degradation after its ubiquitination by the E3 ligase constitutive photomorphogenic protein (COP1) 8 . Glucagon effects were attenuated during late fasting, when CRTC2 was downregulated owing to SIRT1-mediated deacetylation and when FOXO1 supported expression of the gluconeogenic program. Disrupting SIRT1 activity, by liver-specific knockout of the Sirt1 gene or by administration of a SIRT1 antagonist, increased CRTC2 activity and glucose output, whereas exposure to SIRT1 agonists reduced them. In view of the reciprocal activation of FOXO1 and its coactivator peroxisome proliferator-activated receptor-c coactivator-1a (PGC-1a, encoded by Ppargc1a) by SIRT1 activators [9] [10] [11] [12] , our results illustrate how the exchange of two gluconeogenic regulators during fasting maintains energy balance.
We compared the effects of short-and long-term fasting on hepatic CRTC2 activity in mice using an adenoviral CRE-luciferase (Ad-CRE-luc) reporter. Fasting for 6 h induced Ad-CRE-luc activity; these effects were augmented by intraperitoneal glucagon injection ( Fig. 1a and Supplementary Fig. 1 ). Hepatic Ad-CRE-luc activity returned to near basal levels after 18-24 h of fasting, when circulating ketone bodies were highest and when hepatic gluconeogenesis was reduced (Fig. 1a , top and Supplementary Fig. 2) 13 . In keeping with the decrease in gluconeogenic gene expression, hepatic CRTC2 protein amounts were also downregulated in response to prolonged fasting (Fig. 1a , bottom, and Supplementary Figs 1 and 3) .
The E3 ligase COP1 has been shown to silence the gluconeogenic program during refeeding by the ubiquitin-dependent degradation of CRTC2 (ref. 8) . Although undetectable in 6-h-fasted mice, *These authors contributed equally to this work. 1 ubiquitinated CRTC2 protein amounts increased after 18 h of fasting ( Supplementary Fig. 3 ). Indeed, prolonged exposure to glucagon triggered CRTC2 degradation in primary hepatocytes; these effects were blocked by treatment with the proteasome inhibitor MG132 and by RNA interference (RNAi)-mediated depletion of COP1 ( Supplementary Figs 4 and 5) . In contrast to CRTC2, hepatic FOXO1 protein levels remained constant during fasting, suggesting that these transcriptional regulators are differentially regulated (Fig. 1a , bottom, and Supplementary  Fig. 3 ). To test this idea, we used an adenoviral G6Pase (also known as G6pc)-luciferase (Ad-G6Pase-luc) reporter, which contains FOXO1 and CREB binding sites that mediate induction of the G6Pase gene during fasting [14] [15] [16] [17] [18] . Relative to feeding, hepatic Ad-G6Pase-luc activity increased markedly after fasting for 6 h ( Supplementary Fig. 6 ). In contrast to the complete suppression of Ad-CRE-luc activity thereafter, however, Ad-G6Pase-luc activity decreased by only 50% after 18 h ( Fig. 1b) .
We performed knockdown studies to determine the regulatory contributions of CRTC2 and FOXO1 during fasting. RNAi-mediated depletion of hepatic CRTC2 reduced the gluconeogenic profile, which includes Ad-G6Pase-luc activity, gluconeogenic gene expression, and circulating blood glucose concentrations in short-term fasted mice, whereas depletion of FOXO1 had only modest effects at this time (Fig. 1b, c and Supplementary Fig. 7 ). In contrast, FOXO1 knockdown substantially reduced the gluconeogenic profile after 18 h of fasting, when CRTC2 was degraded.
We tested the relative importance of CREB and FOXO1 promoter binding sites for G6Pase gene expression during short-and long-term fasting. Mutation of the cyclic AMP response element (CRE) blocked Ad-G6Pase-luc induction during short-term fasting but had no effect during long-term fasting (Fig. 1d ). Conversely, mutation of FOXO1 binding sites (insulin response elements, IREs) disrupted G6Pase reporter activity during long-term but not short-term fasting. We observed similar effects of CREB and FOXO1 binding sites on G6Pase promoter activity in cultured HepG2 cells exposed for 6 or 18 h to forskolin (FSK; Supplementary Fig. 8 ). Consistent with this activation profile, CRTC2 occupancy over the G6Pase promoter was maximal after short-term exposure to FSK, and returned to baseline levels after 18 h (Fig. 1d , bottom and Supplementary Fig. 8 ). In contrast, FOXO1 occupancy was low at 6 h and increased after 18 h, indicating that CRTC2 and FOXO1 probably regulate gluconeogenic gene expression sequentially in response to fasting.
We reasoned that CRTC2 activity during fasting may be regulated by lysine acetylation, because this modification has been shown to protect certain activators against ubiquitin-mediated degradation 19 . Supporting this idea, fasting led to CRTC2 acetylation after 8 h and to CRTC2 ubiquitination after 24 h ( Fig. 2a, top) . Exposure of primary hepatocytes to glucagon also triggered CRTC2 acetylation; these effects were reversed by subsequent exposure to insulin (Supplementary Fig. 9 ).
Using mass spectrometry to characterize residues in CRTC2 that undergo acetylation, we found a single site at Lys 628, also corresponding to the principal ubiquitination site in CRTC2 ( Supplementary Fig.  10 ) 8 . We confirmed these findings using wild-type and Lys628Arg mutant CRTC2 constructs; exposure to FSK increased the acetylation of wild-type but not Lys628Arg mutant CRTC2 (Fig. 2a, bottom) . Consistent with an important role for Lys 628 in modulating CRTC2 activity, Ad-CRE-luc activity, circulating glucose levels and CRTC2 protein amounts were increased in mice expressing mutant Lys628Arg CRTC2 compared to wild-type CRTC2 during prolonged fasting ( Fig. 2b and Supplementary Fig. 11 ).
CRTC2 has been found to promote CREB target gene expression through an association with the histone acetyltransferase (HAT) paralogues CREB binding protein (CBP; also known as CREBBP) and p300 (ref. 20) . Indeed, short-term fasting increased the CRTC2-p300 interaction in liver, whereas long-term fasting disrupted it ( Fig. 2a ). Exposure to glucagon or FSK also triggered this association in primary hepatocytes; these effects were blocked by subsequent exposure to insulin ( Supplementary Figs 5 and 12 ).
During the course of studies to determine how insulin and glucagon regulate the CRTC2-p300 interaction, we noted that, similar to CRTC2, p300 and CBP contain a consensus recognition motif for the salk inducible kinase 2 (SIK2), which is at Ser 89 in p300 (YXBS/TXSXXXY, in which Y is a hydrophobic residue and B is a basic amino acid; p300, LLRSGSSPNL). Indeed, phosphorylation of p300 at Ser 89 has been reported to inhibit its transcriptional activity, although the underlying mechanism is unclear 21, 22 . Under basal conditions, p300 was phosphorylated at Ser 89 in primary hepatocytes (Fig. 2c, top) . Consistent with the upregulation of hepatic SIK2 activity during feeding and inhibition during fasting 8 , the amounts of Ser 89-phosphorylated p300 increased when cells were exposed to insulin, and they decreased after treatment with glucagon. RNAimediated depletion of SIK2 reduced amounts of Ser 89-phosphorylated p300 in cells exposed to insulin, indicating that p300 is probably protein amounts in primary hepatocytes exposed to glucagon (GLU; 2 h) followed by insulin (INS; 1 h) . The effect of Ad-Sik2 RNAi relative to control (US RNAi) is shown. Bottom, Ad-CRE-luc reporter activity (left) and G6Pase mRNA amounts (right) in primary hepatocytes expressing wild-type or Ser89Ala mutant p300. Exposure to FSK or glucagon (6 h) are indicated; Ctrl, control; GFP, green fluorescent protein; n 5 3; **P , 0.001. d, Top, effect of Ad-p300 RNAi on amounts of acetylated CRTC2 (top) in hepatocytes exposed to glucagon for 1 h. Bottom, effect of Ad-p300 RNAi on Ad-CRE-luc reporter activity (bottom) in hepatocytes exposed to FSK for 6 h; n 5 3, *P , 0.001. For b-d, data are mean 6 s.e.m. a direct substrate for this kinase. Moreover, SIK2 immunoprecipitates were able to phosphorylate wild-type but not mutant-Ser89Ala p300 in vitro ( Supplementary Fig. 13 ).
To investigate the potential role of Ser 89 phosphorylation in regulating p300 activity, we prepared a phosphorylation-defective (Ser89Ala) p300 expression virus. Relative to wild-type p300, mutant-Ser89Ala p300 associated with CRTC2 more efficiently in cells that were exposed to glucagon and insulin ( Supplementary  Fig. 14) . Furthermore, mutant-Ser89Ala p300 was more effective than wild-type p300 in potentiating Ad-CRE-luc reporter activity and gluconeogenic gene expression, confirming the importance of p300 dephosphorylation for CRTC2 induction (Fig. 2c, bottom) .
Because they both have intrinsic HAT activity, CBP and p300 might be expected to modulate CRTC2 activity in part through acetylation. Indeed, overexpression of CBP increased the amounts of acetylated CRTC2 in cells exposed to FSK or to staurosporine, a SIK2 kinase inhibitor ( Supplementary Fig. 15 ). The effects of p300 and CBP seem to be direct, because purified recombinant p300 protein was capable of acetylating a CRTC2 polypeptide containing the Lys 628 acetylation site in vitro ( Supplementary Fig. 15 ). Conversely, RNAi-mediated depletion of p300 reduced CRTC2 acetylation and decreased Ad-CRE-luc activity in hepatocytes exposed to glucagon ( Fig. 2d and Supplementary Fig. 16 ).
We evaluated the role of p300 and CBP in modulating gluconeogenesis through CRTC2. RNAi-mediated depletion of hepatic p300, and to a lesser extent CBP, reduced the gluconeogenic profile in 6-hfasted mice (Fig. 3a) . Hepatic CRTC2 protein amounts were also decreased in p300-depleted mice, suggesting that p300 is required to prevent hepatic CRTC2 degradation during fasting ( Supplementary  Fig. 16 ).
We tested the importance of p300 and CBP HAT activity for CRTC2-dependent gluconeogenesis. The addition of a cell-permeable p300 and CBP HAT inhibitor Lys-CoA-TAT 23, 24 to cultured hepatocytes reduced amounts of acetylated CRTC2, and correspondingly enhanced CRTC2 ubiquitination and degradation (Fig. 3b, top) . Ad-CRE-luc reporter activity and glucose output were consequently downregulated in hepatocytes exposed to Lys-CoA-TAT (Fig. 3b , bottom). These effects were blocked in cells expressing acetylation/ubiquitination-defective Lys628Arg CRTC2 but not wild-type CRTC2 ( Fig. 3c and Supplementary Fig. 17 ). Lys-CoA-TAT administration also reduced the gluconeogenic profile in fasted mice ( Fig. 3d and Supplementary Fig. 17 ), demonstrating the importance of p300 and CBP HAT activity for hepatic glucose production through CRTC2.
Having found that hepatic CRTC2 is deacetylated during prolonged fasting, we considered the involvement of a CRTC2 deacetylase in this process. Recently, the histone deacetylase SIRT1 has been shown to promote energy balance by modulating cellular gene expression in response to nutrient deprivation 25 . Indeed, SIRT1 activators have been found to improve glucose homeostasis in insulinresistant animals by reducing hepatic gluconeogenesis, although, paradoxically, they increase the activity of FOXO1 and its coactivator PGC-1a 9, 11, 26, 27 . Hepatic SIRT1 protein accumulated after 18 h of fasting, when CRTC2 acetylation and protein amounts were correspondingly reduced (Fig. 4a, top left) 9 . In line with these changes, we recovered CRTC2 from immunoprecipitates of SIRT1 prepared from livers of long-term-but not short-term-fasted mice. Moreover, Ad-SIRT1 overexpression in primary hepatocytes reduced the amounts of acetylated and total CRTC2 protein and decreased Ad-CRE-luc activity after exposure to glucagon (Fig. 4a, bottom, and Supplementary Figs 18 and 19) . We observed similar inhibitory effects of Ad-SIRT1 on Ad-CRE-luc reporter activity and circulating blood glucose levels in vivo (Fig. 4a, right and Supplementary Fig. 19 ).
We proposed that SIRT1 activators may also attenuate the gluconeogenic program during fasting through the inhibition of CRTC2. Induction of SIRT1 activity with SRT1720 (ref. 26) or resveratrol reduced the amounts of acetylated CRTC2 and lowered Ad-CRE-luc activity in primary hepatocytes exposed to FSK or glucagon (Fig. 4b,   top , and Supplementary Fig. 20) . Consistent with its ability to lower circulating blood glucose concentrations in part through inhibition of hepatic gluconeogenesis 26 , SRT1720 also decreased the amounts of acetylated hepatic CRTC2 in Zucker fa/fa rats (Fig. 4b, bottom) . In contrast, SRT1720 did not alter Ad-CRE-luc activity or glucose output from hepatocytes expressing acetylation/ubiquitination-defective Lys628Arg CRTC2 ( Supplementary Figs 17 and 21) .
On the basis of these results, we tested, conversely, whether SIRT1 inhibitors increase CRTC2 activity. Exposure of primary hepatocytes to the SIRT1 antagonists sirtinol and nicotinamide enhanced CRTC2 acetylation and Ad-CRE-luc reporter activity in glucagon-stimulated cells (Fig. 4c, top and Supplementary Fig. 22 ). Intraperitoneal sirtinol administration also augmented hepatic Ad-CRE-luc reporter activity during prolonged fasting, when CRTC2 activity is normally downregulated (Fig. 4c, bottom) .
We tested the role of SIRT1 further using mice with a liver-specific knockout of the Sirt1 gene. Under basal conditions, CRTC2 protein LETTERS amounts were comparable in primary cultures of Sirt1 2/2 and wildtype hepatocytes (Fig. 4d, top) . In contrast to the degradation of CRTC2 after prolonged exposure of wild-type cells to glucagon, however, CRTC2 protein amounts remained elevated in Sirt1 2/2 cells. We observed similar differences in hepatic CRTC2 protein amounts between wild-type and Sirt1 2/2 mice during fasting ( Supplementary Fig. 23 ). As a result, hepatic Ad-CRE-luc activity was elevated and unresponsive to sirtinol administration in fasted Sirt1 2/2 mice ( Supplementary Fig. 23 ). Ad-CRE-luc activity and gluconeogenic gene expression were also increased in Sirt1 2/2 hepatocytes after glucagon exposure, demonstrating the importance of this deacetylase in modulating CRTC2 activity (Fig. 4d, bottom and Supplementary Fig. 24 ).
Taken together, these results indicate that fasting signals increase the gluconeogenic program transiently through the acetylation of CRTC2 by p300 and CBP ( Supplementary Fig. 25 ). During prolonged fasting, SIRT1 deacetylates CRTC2 and promotes its ubiquitindependent degradation by COP1. The reciprocal upregulation of FOXO1 activity by SIRT1 during this period seems to be critical in maintaining energy balance through its effects on glucose metabolism 6 . Studies into the mechanism by which nutrient signals modulate p300 and SIRT1 activities should provide further insight into this process.
METHODS SUMMARY
In vivo imaging studies with Ad-CRE-luc and Ad-G6Pase-luc reporters were performed with an IVIS 100 Imaging System 8 . For nutritional studies, mice were evaluated under ad libitum, short-term-fasted (6-8 h), or long-term-fasted (18-24 h) conditions. Adenoviral expression vectors and RNAi constructs for Sirt1, p300 and Cbp were generated as described 7 . Fasting gluconeogenesis was evaluated using 14 C-labelled Ala as reported 28 . Wild-type and Sirt1 2/2 primary hepatocytes were cultured, and glucose output was measured enzymatically after collection in medium containing lactate and pyruvate 8 . p300 and CBP HAT activity was inhibited by the administration of Lys-CoA-TAT in vivo and in cultured hepatocytes 24 . Right, effect of Ad-SIRT1 expression on Ad-CRE-luc activity in 8-h-fasted mice (top) and on CRTC2 acetylation in hepatocytes exposed to glucagon (GLU; bottom); n 5 3; *P , 0.001. b, Top, Ad-CRE-luc activity in primary hepatocytes exposed to SIRT1 activators resveratrol (RES) or SRT1720 (SRT); n 5 3; *P , 0.001. Bottom, immunoblot showing amounts of acetylated (Ac) CRTC2 in livers of Zucker fa/fa obese rats maintained on chow supplemented with SRT1720; n 5 4; *P , 0.05. c, Top, immunoblot of acetylated and total CRTC2 protein in primary hepatocytes exposed to sirtinol and/or glucagon for 4 h. Bottom, Ad-CRE-luc activity in 6-h-or 24h-fasted mice after sirtinol administration. d, Total and acetylated CRTC2 protein amounts (top) and Ad-CRE-luc activity (bottom) in primary hepatocytes from control (WT) or liver-specific Sirt1 2/2 (KO) mice. Exposure to glucagon (6 h) is indicated; n 5 4; *P , 0.05. For a, b and d, data are mean 6 s.e.m.
METHODS
Adenoviruses and animals. Wild-type CRTC2, mutant-Lys628Arg CRTC2, Ad-CRE-luc, Ad-RSV-b-gal (Rous sarcoma virus promoter) and Ad-SIRT1 adenoviruses have been described 8, 9 . The Ad-G6Pase-luc reporter was constructed by the insertion of G6Pase-luc into pShuttle vector and by transferring this cassette to AdEasy by non-homologous recombination. Ad-p300 RNAi was constructed using the sequence ACTTACCAGATGAATTAA. For live imaging experiments, 10 9 plaque forming units (p.f.u.) Ad-CRE-luc and 5 3 10 7 p.f.u. Ad-RSV-b-gal were delivered to 8-10-week-old male mice (Jackson Laboratories) by tail-vein injection. Mice were imaged on day 3-5 after adenovirus delivery. For other in vivo studies, 1 3 10 8 p.f.u. of overexpressing or RNAi adenovirus was used. SIRT1 liver-specific knockout mice were generated by crossing an SIRT1 allele containing a floxed exon 4 (ref. 29) with Cre-expressing mice driven by the liverspecific albumin promoter. Measurement of gluconeogenesis rates in vivo. Fed, 6-h-and 24-h-fasted mice were injected intraperitoneally with labelled precursor (5mCi of [U-14 C]Ala) and blood samples were analysed after 30 min, when 14 C incorporation into glucose is still linear. Gluconeogenesis rates in vivo were determined as described previously 28 . Results are expressed as glucose synthesized in mmol h 21 g 21 body weight. The separation of labelled glucose from labelled alanine and other charged compounds was performed by ion exchange chromatography. A neutralized aliquot of blood barium hydroxide-zinc sulphate was passed onto a layered bed resin column, consisting of Dowex-1-X8 (200-400 mesh) in the formate form and Dowex-50W-X8 (200-400 mesh) in the H 1 form. The sample was eluted with water, and labelled glucose contained in the eluate was assayed for radioactivity in a scintillation spectrometer. To determine whether glucose was indeed collected in the eluate, glucose was transformed into glucose 6-phosphate (G6P) by hexokinase in the presence of ATP. G6P was then absorbed into a column of Dowex-1-X8. By using this method, more than 95% of the counts found in this eluate were absorbed on the column, showing that 95% of labelled substrate on the glucose eluate was glucose, converted to G6P after incubation with hexokinase and ATP. The method thus provides a reliable estimate of the 14 C glucose formed from 14 C Ala. In vivo imaging and analysis. For imaging, mice were injected intraperitoneally with 50 mg kg 21 nembutal (Abbott Laboratories) and 100 mg kg 21 sterile firefly D-luciferin (Xenogen). Mice were imaged on the IVIS 100 Imaging System, and analysed with Living Image software (Xenogen). Luciferase activity from Ad-CREluc and Ad-G6Pase-luc reporters was normalized to b-glactosidase activity from co-injected RSV-b-gal plasmid as described previously 8 . For studies comparing mutant and wild-type G6Pase reporters (Fig. 1e ), activities were also normalized to reporter DNA from hepatic lysates by quantitative-PCR analysis. For Lys-CoA-TAT studies, mice were injected intraperitoneally with Lys-CoA-TAT
